IPX054 250 mg ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	2

6. Parkinson disease

---

Clinical trials : 2,298 /  Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00279825 (ClinicalTrials.gov)	January 2006	18/1/2006	Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease	A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Compare IPX054 200 mg and 250 mg to CD-LD IR 200 (2x100) mg Tablets and CD-LD CR 200 mg Tablet in Subjects With Parkinson's Disease	Idiopathic Parkinson's Disease	Drug: IPX054 200 mg;Drug: IPX054 250 mg;Drug: CD-LD IR;Drug: CD-LD CR;Drug: IPX054 200 mg Placebo;Drug: IPX054 250 mg Placebo;Drug: CD-LD IR Placebo;Drug: CD-LD CR Placebo	Impax Laboratories, LLC	NULL	Completed	30 Years	N/A	All	16	Phase 2	United States
2	NCT00239564 (ClinicalTrials.gov)	October 2005	13/10/2005	Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease	An Open-Label Study to Assess the Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease	Idiopathic Parkinson's Disease	Drug: IPX054 100 mg;Drug: IPX054 150 mg;Drug: IPX054 200 mg;Drug: IPX054 250 mg;Drug: IPX054 300 mg	Impax Laboratories, LLC	NULL	Completed	30 Years	N/A	All	12	Phase 1/Phase 2	United States